Bristol-Myers Will Divest Celgene Blockbuster to Close Deal




 

(Bloomberg) -- Bristol-Myers Squibb Co. agreed to divest one of Celgene Corp.'s most lucrative drugs in order to close their planned $74 billion merger.

Under an agreement with the Federal Trade Commission, Bristol-Myers will sell off the psoriasis pill Otezla to appease antitrust regulators' concerns, the company said in a statement.

Bristol-Myers shares fell as much as 7% to $45.89 in New York, the biggest intraday drop since the deal was announced on Jan. 3. Celgene declined as much as 4.7% to $94.26.

Otezla is a major product for Celgene, bringing in $1.86 billion last year, and was seen as an important driver of future growth as the two companies knit together their businesses. Bristol-Myers has been battling Merck & Co. for dominance in the field of cancer immunotherapy, while Celgene's blockbuster Revlimid for blood cancers is expected to face lower-priced competitors in coming years.

Otezla has as much as a decade of strong sales ahead, according to analysts' estimates surveyed by Bloomberg. Now, a rival drugmaker will get the rights to the pill, potentially at a discounted price. Johnson & Johnson's Janssen unit has said it's interested in pursuing an oral psoriasis treatment through an acquisition or its own pipeline.

Bristol-Myers is researching another type of therapy for psoriasis known as a TYK2-inhibitor that would likely compete with Celgene's blockbuster drug. While the drugs work differently, the overlap raised concerns from regulators, according to the statement. By divesting Otezla, Bristol-Myers is electing to sell a blockbuster in favor of a promising, though still experimental, therapy.

"Divesting Otezla a surprise to us and removes one of the newco's growth drivers," Vamil Divan, an analyst with Credit Suisse Group AG, said in a note to clients.

Taking Longer

Bristol-Myers also said that the deal will take longer to close than it had expected. Its new target is the end of 2019 or early 2020, pushed back from a previous goal of Sept. 30. The FTC review is ongoing, the company said, and European regulators will review it as well.

"Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene," the company said in the statement. It plans to use the proceeds to pay off debt.

The increased oversight spooked investors in another biotechnology company facing regulatory review. Earlier this month, the FTC requested more information about Spark Therapeutics Inc.'s proposed sale to Roche Holding AG, sending the gene therapy company's shares falling. Spark's shares dropped as much as 3.6% to $101.25 on the news of the Otezla divestiture.

In a research note, Jefferies analyst Michael Yee said it remains to be seen what the news could mean for the industry.

"We continue to be mindful and are carefully watching to get a better handle on if we are in a more aggressive FTC era for biotech," he wrote in a note to clients.

Separately, Bristol-Myers said that its cancer drug Opdivo, its No. 2 product, had failed a clinical trial treating liver cancer patients. The medicine faces multiple competitors that use the same mechanism to help the immune system attack tumors, and Bristol-Myers' rivals have been attempting to get the drugs approved in as many different types of cancer as possible.

(Updates with details about Bristol-Myers's psoriasis treatment in fourth paragraph.)

To contact the reporters on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net;Riley Griffin in New York at rgriffin42@bloomberg.net

To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Mark Schoifet, Timothy Annett

For more articles like this, please visit us at bloomberg.com

©2019 Bloomberg L.P.

COMMENTS

More Related News

Kodak
Kodak's $765 Million Government Loan on Hold Pending Probe

(Bloomberg) -- The federal agency that announced a $765 million loan to Eastman Kodak Co. less than two weeks ago said the offer is on hold pending probes into allegations of wrongdoing."Recent allegations of wrongdoing raise serious concerns," the U.S. International Development Finance Corporation said in a tweet Friday night. "We will not proceed any further unless these allegations are cleared." Congress and the Securities and Exchange Commission are investigating the deal, and Kodak's board said Friday it is also opening a review of the loan disclosure.The development bank loan announced July 28 was the first of its kind under the Defense Production Act in collaboration with the U.S....

Buffett Bought Up His Own Stock While Selling Others Amid Rally
Buffett Bought Up His Own Stock While Selling Others Amid Rally

(Bloomberg) -- Shares of Berkshire Hathaway Inc. were left out of the stock market rally in the second quarter. Warren Buffett clearly thought the disconnect wasn't warranted.The famed investor spent a record $5.1 billion buying back Berkshire's own stock in the second quarter, more than double the amount he'd ever purchased before. That came as he unloaded almost $13 billion of other companies' shares, including airline stocks and some financials, in what was Buffett's biggest selling quarter in more than a decade.Buffett has shown signs of buying appetite in recent weeks, but the second-quarter results show those are a new phenomenon as the Covid-19 pandemic has slammed the economy but...

Susan Rice Sells Netflix Options as Biden
Susan Rice Sells Netflix Options as Biden's Running Mate Decision Nears

(Bloomberg) -- Former national security adviser Susan Rice, a Netflix director, sold some of her shares of the video streaming company worth $305,323 this week as speculation swirls that she is among the candidates to be Democratic presidential nominee Joe Biden's running mate.A spokeswoman for Rice said the sale was unrelated to politics and was made under a stock trading plan she filed more than three months ago under Securities and Exchange Commission rules."Ambassador Rice's sale of a fraction of her Netflix stock has nothing to do with VP speculation," Erin Pelton said.Rice, who also served as the U.S. ambassador to the United Nations, is being vetted as a possible running mate for...

Stimulus Talks Near Collapse Amid White House-Democratic Rancor
Stimulus Talks Near Collapse Amid White House-Democratic Rancor

(Bloomberg) -- Negotiations on a new coronavirus relief bill edged toward the brink of collapse after a meeting Thursday between White House officials and top congressional Democrats ended with each side accusing the other of being unwilling to compromise and the biggest issues far from resolved.The

Will Macron Deliver on His Lofty Promises to Help Beirut?
Will Macron Deliver on His Lofty Promises to Help Beirut?
  • World
  • 2020-08-07 12:03:12Z

(Bloomberg Opinion) -- There were moments during Emmanuel Macron's visit to Beirut on Thursday when it seemed that the French president was in a mosh pit, crowd-surfing over waves of adulation and anger: The adulation was for him, and far more than he might reasonably expect from a Parisian throng; the anger was for the entire Lebanese political class, who are being collectively blamed for the devastating blasts that shattered much of the city on Tuesday.    It is easy enough to cavil, as some have, that Macron's walkabout in the Gemmayzeh neighborhood was political theater. He was always going to get a friendlier reception in a Francophile quarter of East Beirut than, say, in the...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Economy